Julia Bonavitacola

A vaccine for adults 60 years and older was approved by the FDA for protection against respiratory syncytial virus, making it the first such vaccine to be approved worldwide.

Further epidemiologic studies on nonpharmaceutical interventions are warranted to assess their relationship with respiratory syncytial virus (RSV).

When presented with a set of multiple choice questions used to help trainees practice for the ophthalmology board certification exams, the artificial intelligence (AI) chatbot ChatGPT was able to answer only half correctly.

Reducing disparities in the treatment of atopic dermatitis (AD) was the focus of a session of the final day of the Revolutionizing Atopic Dermatitis 2023 conference.

A panel held at Revolutionizing Atopic Dermatitis 2023 reviewed therapies to expect within the next year for the treatment of atopic dermatitis (AD) as well as investigational therapies currently undergoing trials.

Janus kinase (JAK) and phosphodiesterase-4 (PDE-4) inhibitors were primary topics covered at the third symposium at the Revolutionizing Atopic Dermatitis fifth annual conference.

A. Mark Fendrick, MD, co–editor in chief of The American Journal of Managed Care® and director of the V-BID Center at the University of Michigan, discusses how the Braidwood ruling can affect the efficacy of preventive care.

In posters presented at the Revolutionizing Atopic Dermatitis conference, ruxolitinib cream was found to be both safe and effective in treating atopic dermatitis (AD).

Researchers found that eyeglasses with traditional steps of 0.25D were less effective and less preferred by participants compared with those refracted in 0.05D steps.

The Revolutionizing Atopic Dermatitis conference, set to begin on April 29 in Washington, DC, promises to offer symposia on emerging therapies and new insights into treating atopic dermatitis (AD).

A nomogram that could assist physicians in predicting severe respiratory syncytial virus (RSV)–associated bronchiolitis early on was established and validated in a recent study.

A new study found that the MVA-BN-RSV vaccine was able to lower symptom scores and resulted in fewer confirmed RSV infections vs placebo.

Nicholas Bagley, JD, of Michigan Law, University of Michigan, explained what the Braidwood v Becerra court case was about and how the ruling affected preventive care across the country.

Although the 28-day mortality for patients with respiratory failure did not differ between patients with and without respiratory syncytial virus (RSV), complications were more common in those with RSV.

Retinopathy of prematurity (ROP) was found to have increased from 2003 to 2019, especially in Black and Hispanic children.

Although new guidelines from the CDC say that masks need not be worn in counties where transmission level for COVID-19 isn’t high, many health systems still plan to mask.

Long-term temporal and spatial trends, as well as changes, can be estimated using hospital admission data when the burden on health care systems is increased.

Perfluorohexyloctane (NOV03) was able to reduce the signs and symptoms of dry eye disease (DED) when compared with hypotonic saline control and was well tolerated.

Patients who had limited proficiency with English or preferred the use of another language had increased hospitalization and death rates if they delayed time to their first dose of the vaccine.

Patients who were admitted to the hospital for respiratory syncytial virus (RSV) had a higher risk of a complex hospital course and had higher rates of respiratory support compared with patients admitted for influenza.

A recent study found the mortality rate for patients hospitalized for respiratory syncytial virus (RSV) to be 6.6%, with approximately 25% of hospitalized patients requiring admission to the intensive care unit.

A new study has found that respiratory syncytial virus (RSV) infections were more frequent and severe compared with influenza A/B in older adults.

A ruling by District Judge Reed O’Connor on March 30 called the future of preventive care access into question.

Treatment for age-related macular degeneration (AMD) and diabetic macular edema (DME) for a single year was found to be lowest when using bevacizumab.

The incidence of respiratory syncytial virus (RSV)–positive acute respiratory infection (ARI) was found to be significant in the period prior to the COVID-19 pandemic in older adults.

Associated hospitalization burden could be 2.2 times higher in older adults with respiratory syncytial virus (RSV) than was previously estimated, according to a recent study.

Protection against COVID-19 and vaccine effectiveness increased after receiving 1 or 2 booster doses compared with a primary series alone, but vaccine effectiveness generally declined as the time since last dose increased.

American Indians and Alaska Native individuals had lower estimates of incidence of diabetic retinopathy than had been reported.

A recent study found that chatbot systems that used artificial intelligence (AI) could be valuable in providing access to current, accurate, and complete information about infectious diseases and vaccines against them.

A systematic review found that there were currently a limited number of clinical trials evaluating treatment for dry eye disease (DED) that is associated with meibomian gland dysfunction (MGD).